Cargando…

Successful Rechallenge with Osimertinib after Very Acute Onset of Drug-Induced Pneumonitis

Drug-induced interstitial lung disease (DI-ILD) is a rare, yet life-threatening complication associated with tyrosine-kinase inhibitor (TKI) therapy. Third-generation epidermal growth factor receptor-TKI, osimertinib use can be associated with a benign radiological finding called transient asymptoma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mohammed, Turab, Mangeshkar, Shaunak, Rathmann, Joerg
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8216030/ https://www.ncbi.nlm.nih.gov/pubmed/34177523 http://dx.doi.org/10.1159/000516274

Ejemplares similares

Successful osimertinib rechallenge after osimertinib-induced pneumonitis in a patient with lung adenocarcinoma
por: Satoh, Shingo, et al.
Publicado: (2017)

Successful osimertinib rechallenge following drug-induced pneumonitis after previous anti-PDL1 exposure
por: Harada, Guilherme, et al.
Publicado: (2019)

Osimertinib rechallenge under steroid protection following osimertinib-induced pneumonitis: three case studies
por: Bickert, Christiane, et al.
Publicado: (2021)

Successful Osimertinib Rechallenge with Steroid Therapy after Osimertinib-induced Interstitial Lung Disease
por: Kiriu, Tatsunori, et al.
Publicado: (2017)

Successful Rechallenge with Osimertinib following Osimertinib-Induced Ventricular Tachycardia: A Case Report
por: Saito, Zentaro, et al.
Publicado: (2023)

Osimertinib‐related liver injury with successful osimertinib rechallenge: A case report
por: Cheng, Yuan‐Ling, et al.
Publicado: (2022)

Successful treatment with afatinib following the failure of osimertinib rechallenge with osimertinib-induced interstitial lung disease: A case report
por: Sato, Yozo, et al.
Publicado: (2021)

5-Fluorouracil Rechallenge After Cardiotoxicity
por: Desai, Aakash, et al.
Publicado: (2020)

Successful osimertinib retreatment after extremely early onset severe pneumonitis in first‐line treatment of lung adenocarcinoma
por: Ahn, June Hong
Publicado: (2020)

Successful osimertinib rechallenge in a patient with advanced non-small cell lung cancer following osimertinib-induced interstitial lung disease after treatment with nivolumab
por: Mamesaya, Nobuaki, et al.
Publicado: (2017)

Osimertinib: Pneumonitis: case report
Publicado: (2021)

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
por: Cui, Qingli, et al.
Publicado: (2022)

Taxane-induced acute interstitial pneumonitis in patients with breast cancer and outcome of taxane rechallenge
por: Anoop, T M, et al.
Publicado: (2022)

OSIMERTINIB PNEUMONITIS MASQUERADING AS COVID-19 PNEUMONIA
por: ALHALABI, ELIANE, et al.
Publicado: (2021)

Successful Rechallenge with Imatinib in a Patient with Chronic Myeloid Leukemia Who Previously Experienced Imatinib Mesylate Induced Pneumonitis
por: Go, Seong Woo, et al.
Publicado: (2013)

Brief Report: Severe Pneumonitis After Combined Thoracic Radiotherapy and Osimertinib
por: Smith, Clayton P., et al.
Publicado: (2023)

Osimertinib: Pneumonitis and interstitial lung disease: case report
Publicado: (2022)

Rechallenge of voriconazole successfully tolerated after hepatic toxicity
por: Narumoto, O., et al.
Publicado: (2020)

Survival benefit of combinatorial osimertinib rechallenge and entrectinib in an EGFR‐mutant NSCLC patient with acquired LMNA‐NTRK1 fusion following osimertinib resistance
por: Wang, Jiao‐Li, et al.
Publicado: (2022)

Rechallenge with erlotinib in osimertinib-resistant lung adenocarcinoma mediated by driver gene loss: a case report
por: Liu, Lingli, et al.
Publicado: (2020)

Early‐onset interstitial pneumonitis in a patient with advanced non‐small cell lung cancer treated with crizotinib and osimertinib
por: Cheng, Yuan, et al.
Publicado: (2021)

Successful retreatment with osimertinib after osimertinib-induced acute pulmonary embolism in a patient with lung adenocarcinoma: A case report
por: Shiroyama, Takayuki, et al.
Publicado: (2016)

Pneumonitis in Patients Receiving Thoracic Radiotherapy and Osimertinib: A Multi-Institutional Study
por: Banla, Leou Ismael, et al.
Publicado: (2023)

Successful erlotinib rechallenge after both gefitinib- and erlotinib-induced interstitial lung diseases
por: Arakawa, Nobuhito, et al.
Publicado: (2013)

Nodule‐type pneumonitis mimicking lung abscess or tumor recurrence on chest computed tomography identified as osimertinib‐induced pneumonitis: A case report
por: Otsuki, Ayumu, et al.
Publicado: (2022)

Successful capecitabine rechallenge following 5-fluorouracil-induced Takotsubo syndrome
por: Abdelrahman, Mohamed, et al.
Publicado: (2016)

Acute Interstitial Lung Disease Induced by Rechallenge with Ceritinib
por: Hotta, Takamasa, et al.
Publicado: (2019)

Rechallenge of lamotrigine after development of rash
por: Houser, Jennifer, et al.
Publicado: (2018)

Lithium rechallenge after renal transplant
por: Beasley, Anna K., et al.
Publicado: (2018)

Successful Management of Osimertinib-Induced Heart Failure
por: Fukuo, Atsuko, et al.
Publicado: (2022)

Successful rechallenge for severe lichenoid drug reaction to pembrolizumab presenting as “toxic epidermal necrolysis-like”
por: Eldani, Céline, et al.
Publicado: (2023)

Successful rechallenge with paliperidone after clozapine treatment for a patient with dopamine supersensitivity psychosis
por: Kobayashi, Remiko, et al.
Publicado: (2020)

Successful clozapine rechallenge after neutropenia using lithium carbonate : a case report
por: Khattech, D., et al.
Publicado: (2022)

Successful Trastuzumab-Deruxtecan Rechallenge After Interstitial Lung Disease: A Case Report
por: de Weger, Vincent A., et al.
Publicado: (2023)

Successful immune checkpoint inhibitor rechallenge after immune-related pericarditis: Clinical case series
por: Chye, Adrian M., et al.
Publicado: (2022)

Management of recurrent pleural mesothelioma: Successful rechallenge with nintedanib in combination with chemotherapy
por: Grosso, Federica, et al.
Publicado: (2018)

RECOVERY AND RECHALLENGE AFTER THE NEUROLEPTIC MALIGNANT SYNOROME
por: Chopra, Mohit P., et al.
Publicado: (2001)

Melanoma: BRAFi Rechallenge
por: Kosmidis, Christoforos S., et al.
Publicado: (2023)

Acute-Onset Pneumonitis while Administering the First Dose of Durvalumab
por: Tonk, Erwin H.J., et al.
Publicado: (2019)

Non-Recurrence of Carbamazepine Induced Vitiligo after Rechallenge with Carbamazepine
por: Saeedloo, Masoomeh, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_e22soqa78htdqnc3erp23uv9qk